Format

Send to

Choose Destination
Cancer Chemother Pharmacol. 2018 Sep;82(3):541-550. doi: 10.1007/s00280-018-3646-0. Epub 2018 Jul 20.

A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies.

Author information

1
Department of Medicine, Division of Medical Oncology, Stanford University, Stanford, CA, USA. mdas@stanford.edu.
2
VA Palo Alto Health Care System, 3801 Miranda Avenue, 111-ONC, Palo Alto, CA, 94304-1290, USA. mdas@stanford.edu.
3
Department of Medicine, Division of Medical Oncology, Stanford University, Stanford, CA, USA.
4
Department of Pediatrics, Stanford University, Stanford, CA, USA.
5
Mayo Clinic, Rochester, MN, USA.
6
Exelixis, Inc., South San Francisco, CA, USA.

Abstract

PURPOSE:

To evaluate the safety, tolerability, and pharmacokinetics of XL647 and determine the maximum tolerated dose (MTD) of oral XL647 once-daily using intermittent or continuous dosing schedules.

METHODS:

Patients with advanced solid malignancies were enrolled in successive cohorts to receive escalating dose levels of oral once-daily XL647 using two different dosing schedules: 5 consecutive days of every 14-day cycle (study XL647-001) or continuously over 28-day cycles (study XL647-002). PK sampling was performed to determine Cmax, and AUC. Patients remained on study until progressive disease or unacceptable AEs.

RESULTS:

In XL647-001, 42 individuals were enrolled across 9 dose levels. The most frequently occurring drug-related AEs were diarrhea, nausea, rash, and fatigue. Expansion of the 4.68 mg/kg cohort to 6 patients occurred without further dose-limiting toxicities (DLTs) and this was considered the MTD. In XL647-002, 31 patients were enrolled across 5 dose levels. A DLT of grade 3 pneumonitis occurred in 1/6 patients at 300 mg, which was declared the MTD. The most common AEs included grade 1/2 rash, diarrhea, fatigue, dysgeusia, and QTc prolongation. Levels of pharmacodynamic plasma markers were not consistently changed after XL647 and no conclusions could be drawn with this limited data set.

CONCLUSIONS:

For oral XL647, the MTD was 4.68 mg/kg or 350 mg fixed dose when administered once-daily for 5 consecutive days of every 14-day cycle and was 300 mg when administered once-daily continuously. XL647 was well tolerated at doses up to the MTD.

KEYWORDS:

Angiogenesis; EGFR; Kinase inhibitor; Tesevatinib; VEGFR; XL647

PMID:
30030583
DOI:
10.1007/s00280-018-3646-0
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center